DME Capital Management’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

DME Capital Management’s Portfolio TLIS Stock Details TLIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-149,052	Closed	-$1.29M	–	40
2024 Q2	$1.29M	Hold	149,052	–	–	0.06%	35
2024 Q1	$1.3M	Buy	+149,052	New	+$1.23M	0.06%	38

Other funds holding TLIS

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

DME Capital Management's TLIS Position: Q3 2024 in Review

DME Capital Management sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q3 2024, closing a stake of 149,052 shares — an estimated $1.29M sold.

DME Capital Management first reported a position in TLIS in Q1 2024 and held it in 2 quarters. The position peaked at $1.3M in Q1 2024. 2 funds tracked by Wall St. Rank hold TLIS as of Q3 2024.

DME Capital Management reported no remaining Talis Biomedical Corporation Common Stock position as of Q3 2024 after selling out during the quarter.
DME Capital Management sold 149,052 Talis Biomedical Corporation Common Stock shares in Q3 2024, an estimated $1.29M.
DME Capital Management first reported a position in Talis Biomedical Corporation Common Stock in Q1 2024 and held it in 2 quarters.
DME Capital Management's Talis Biomedical Corporation Common Stock position peaked at $1.3M in Q1 2024.
2 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q3 2024.

Based on DME Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.